Inari Medical (NARI) Projected to Post Quarterly Earnings on Wednesday

Inari Medical (NASDAQ:NARI - Get Free Report) is projected to release its earnings data before the market opens on Wednesday, February 26th. Analysts expect Inari Medical to post earnings of ($0.01) per share and revenue of $160.67 million for the quarter.

Inari Medical Price Performance

Shares of NASDAQ:NARI traded up $0.04 on Friday, hitting $79.97. The company's stock had a trading volume of 2,359,000 shares, compared to its average volume of 1,064,604. The company has a 50-day simple moving average of $71.00 and a 200 day simple moving average of $55.18. Inari Medical has a 1 year low of $36.73 and a 1 year high of $79.99. The company has a market capitalization of $4.68 billion, a PE ratio of -59.24 and a beta of 1.02.

Analyst Ratings Changes

NARI has been the topic of several recent analyst reports. BTIG Research reaffirmed a "neutral" rating on shares of Inari Medical in a report on Wednesday, January 8th. Robert W. Baird reaffirmed a "neutral" rating and issued a $80.00 price target (down previously from $81.00) on shares of Inari Medical in a report on Tuesday, January 7th. Needham & Company LLC reaffirmed a "hold" rating on shares of Inari Medical in a report on Tuesday, October 29th. Canaccord Genuity Group reaffirmed a "hold" rating and issued a $80.00 price target (up previously from $74.00) on shares of Inari Medical in a report on Tuesday, January 7th. Finally, William Blair reissued a "market perform" rating on shares of Inari Medical in a report on Tuesday, January 7th. Twelve equities research analysts have rated the stock with a hold rating and two have issued a buy rating to the stock. According to MarketBeat, the stock has a consensus rating of "Hold" and a consensus target price of $68.00.

Insider Buying and Selling

In related news, Director William Hoffman sold 200,000 shares of the firm's stock in a transaction that occurred on Monday, January 6th. The stock was sold at an average price of $60.47, for a total transaction of $12,094,000.00. Following the transaction, the director now directly owns 238,987 shares in the company, valued at $14,451,543.89. This trade represents a 45.56 % decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, CEO Andrew Hykes sold 3,000 shares of the firm's stock in a transaction that occurred on Friday, December 20th. The stock was sold at an average price of $55.29, for a total value of $165,870.00. Following the transaction, the chief executive officer now owns 439,310 shares in the company, valued at approximately $24,289,449.90. The trade was a 0.68 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold a total of 263,000 shares of company stock worth $15,599,470 in the last ninety days. 10.60% of the stock is owned by insiders.

About Inari Medical

Inari Medical, Inc builds minimally invasive, novel, and catheter-based mechanical thrombectomy devices and accessories for the specific disease states in the United States. The company provides ClotTriever system, which is designed to core, capture, and remove large clots from large vessels for treatment of deep vein thrombosis and peripheral thrombus; FlowTriever system, a large bore catheter-based aspiration and mechanical thrombectomy system to remove large clots from large vessels in the peripheral vasculature for treating pulmonary embolism and other complex venous thromboembolism cases; InThrill system to treat small vessel thrombosis; and LimFlow system for patients who have chronic limb-threatening ischemia with no suitable endovascular or surgical revascularization options and risk of major amputation.